The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling

By Luke A. O'Neill, A. Bowie. Nature reviews. Immunology, 2007

2,817 citations recorded by the source corpus.

Subfields: Cancer Research, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/3b21999307cf33487f8950de612697219c305f25

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Shizuo Akira
2. Jonathan C. Kagan
3. Luke A. O'Neill
4. R. Medzhitov
5. Kui Li
6. Sandra N. Lester
7. A. Cerutti
8. Danyang Li

In Immunology

1. Shizuo Akira
2. R. Medzhitov
3. Jonathan C. Kagan
4. Luke A. O'Neill
5. Danyang Li
6. Minghua Wu
7. Kui Li
8. Sandra N. Lester

In Oncology

1. Shizuo Akira
2. R. Medzhitov
3. Jonathan C. Kagan
4. Luke A. O'Neill
5. A. Cerutti
6. C. Porta
7. Y. Belkaid
8. A. Sica

Citations in the corpus

• Neutrophil cell surface receptors and their intracellular signal transduction pathways (2013, background): “[153,193], resulting in transcriptional regulation of cytokine production and other proinflammatory processes.”
• Microbiota-Dependent Crosstalk Between Macrophages and ILC3 Promotes Intestinal Homeostasis (2014, positive): “Myd88 is an essential signal transducer in both the TLR and IL-1R pathway (50).”
• The interleukin‐1 receptor/Toll‐like receptor superfamily: 10 years of progress (2008, background): “There are five signaling adapters (C) that are recruited to the indicated receptors (55).”
• Pattern recognition receptors in health and diseases (2021, background): “Depending on the different adaptor proteins, TLR signaling can be divided into MyD88-dependent and MyD88-independent pathways.(256) MyD88 has a TIR domain at the C-terminus and a death domain at the Nterminus and is the linker molecule in most TLR signal transduction pathways.”
• The IL-33/ST2 pathway: therapeutic target and novel biomarker (2008, background): “A family of five adaptor molecules comprised of myeloid differentiation factor 88 ( MyD88 ), MyD88-adaptor-like protein ( MAL , also known as TIRAP), TIR-domain-containing adaptor protein inducing IFNβ ( TRIF , also known as TICAM1), TRIF-related adaptor molecule ( TRAM , also known as TICAM2) and s”
• Toll-like receptors in antiviral innate immunity (2013, background): “An additional adaptor protein MAL is required for the interaction of TLR2 to MyD88 [159], acting as a linking adaptor via its TIRdomain [9,160].”